News & Updates

Ultra-low dose EBRT feasible in primary cutaneous B-cell lymphoma
Ultra-low dose EBRT feasible in primary cutaneous B-cell lymphoma
23 Sep 2024

Patients with primary cutaneous B-cell lymphoma (PCBCL) treated with ultra-low dose external beam radiation therapy (EBRT) to 4 Gy total dose in two fractions experience durable local control without skin toxicity, reports a study.

Ultra-low dose EBRT feasible in primary cutaneous B-cell lymphoma
23 Sep 2024
GLP-1 RA benefit may branch out into obesity-related cancers
GLP-1 RA benefit may branch out into obesity-related cancers
17 Sep 2024 byAudrey Abella

Another feather may have been added in the cap of glucagon-like protein-1 receptor agonists (GLP-1 RAs) – the class of type 2 diabetes (T2D) drugs that has become a blockbuster recently due to their remarkable weight loss benefit – as evidence of their potential to reduce the risk of obesity-associated cancers (OACs) comes to light.

GLP-1 RA benefit may branch out into obesity-related cancers
17 Sep 2024